The Oregon DFR further states that the Ninth Circuit issued a decision effective October 31, 2025, overturning that decision, requiring the Department to “resume the collection of mandatory price gouging reports from manufacturers.” The bulletin is directed at all manufacturers of prescription drugs subject to the Oregon program. For insurance industry professionals in Oregon – including insurers, brokers, MGAs, underwriters and compliance teams – the only implication clearly determined is Oregon DFR’s statement that it is resuming collection of mandatory producer price increase reports, with Bulletin DFR 2024-3 no longer in effect.
Oregon DFR withdraws 2024 suspension bulletin and resumes mandatory drug price increase reporting & more related News Here
